Jinling Pharmaceutical Company Limited (SHE:000919)
China · Delayed Price · Currency is CNY 6.07
-0.14 (-2.25%)
Nov 13, 2026, 3:04 PM CST
SHE:000919 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 3,775 | 4,944 | 4,104 | 4,023 | 3,966 | 3,856 | |
Market Cap Growth | -18.19% | 20.47% | 2.02% | 1.43% | 2.86% | -0.52% |
Enterprise Value | 2,371 | 3,630 | 2,644 | 3,503 | 3,076 | 3,156 |
Last Close Price | 6.07 | 7.82 | 6.38 | 7.52 | 7.33 | 7.12 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 84.99 | 91.71 | 101.56 | 37.88 | 37.67 | 31.96 |
Forward PE | - | 20.24 | 20.24 | 20.24 | 20.24 | 20.24 |
PS Ratio | 1.19 | 1.55 | 1.25 | 1.26 | 1.49 | 1.37 |
PB Ratio | 0.78 | 1.02 | 0.85 | 0.91 | 1.09 | 1.09 |
P/TBV Ratio | 1.10 | 1.45 | 1.21 | 1.47 | 1.46 | 1.39 |
P/FCF Ratio | 24.38 | 302.55 | - | - | - | 29.83 |
P/OCF Ratio | 11.72 | 28.38 | 26.62 | 18.97 | 15.22 | 13.20 |
PEG Ratio | - | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 0.75 | 1.14 | 0.81 | 1.10 | 1.15 | 1.12 |
EV/EBITDA Ratio | 14.46 | 21.56 | 14.69 | 15.24 | 17.72 | 10.84 |
EV/EBIT Ratio | 97.04 | 145.41 | 104.48 | 43.33 | 60.28 | 18.65 |
EV/FCF Ratio | 15.31 | 222.11 | - | - | - | 24.42 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.04 | 0.01 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 1.17 | 1.11 | 1.02 | 0.18 | 0.03 | 0.06 |
Debt / FCF Ratio | 1.24 | 11.74 | - | - | - | 0.13 |
Net Debt / Equity Ratio | -0.51 | -0.55 | -0.51 | -0.47 | -0.50 | -0.42 |
Net Debt / EBITDA Ratio | -15.42 | -15.79 | -13.62 | -9.04 | -10.55 | -5.11 |
Net Debt / FCF Ratio | -15.86 | -162.62 | 51.71 | 80.36 | 37.35 | -11.50 |
Asset Turnover | 0.53 | 0.53 | 0.57 | 0.64 | 0.59 | 0.64 |
Inventory Turnover | 10.02 | 10.03 | 9.52 | 9.45 | 8.64 | 9.46 |
Quick Ratio | 3.29 | 3.64 | 3.25 | 2.69 | 2.72 | 2.37 |
Current Ratio | 3.54 | 3.89 | 3.52 | 2.98 | 3.04 | 2.67 |
Return on Equity (ROE) | 0.90% | 1.06% | 0.39% | 3.20% | 3.18% | 4.39% |
Return on Assets (ROA) | 0.25% | 0.26% | 0.27% | 1.01% | 0.71% | 2.42% |
Return on Invested Capital (ROIC) | 0.86% | 0.86% | 0.48% | 3.40% | 2.37% | 6.38% |
Return on Capital Employed (ROCE) | 0.50% | 0.50% | 0.50% | 1.80% | 1.40% | 4.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.18% | 1.09% | 0.98% | 2.64% | 2.66% | 3.13% |
FCF Yield | 4.10% | 0.33% | -1.16% | -0.64% | -1.24% | 3.35% |
Dividend Yield | 1.65% | 1.26% | 1.52% | 1.27% | 1.23% | 1.31% |
Payout Ratio | 140.99% | 125.23% | 156.50% | 48.17% | 48.60% | 42.00% |
Buyback Yield / Dilution | -0.43% | -4.95% | -17.56% | -0.01% | 0.02% | 0.01% |
Total Shareholder Return | 1.21% | -3.69% | -16.04% | 1.27% | 1.25% | 1.32% |